Clinical Trial Update: A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Cinryze for acute antibody-mediated rejection in kidney transplant recipients was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Kidney Transplant Rejection

Drugs mentioned

• Cinryze (C1 esterase inhibitor)

Snippet

Sponsor: Shire | Conditions: Acute Antibody-Mediated Rejection (AMR) | Phase 3 | Status: TERMINATED | Results posted: 2020-07-13